Exelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in colorectal cancer.
Key Takeaways
- Exelixis’s zanzalintinib got over the first hurdle on its way to the market, with positive topline results from the Phase III STELLAR-303 trial in previously treated non-MSI-high metastatic colorectal cancer.
The company announced June 22 topline results from the Phase III STELLAR-303 clinical trial combining zanzalintinib with Roche’s PD-L1 inhibitor...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?